Dr. Reddy’s Labs Vice Chairman G. V. Prasad On Challenges And Opportunities In The Global Generic Drugs Industry: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
In the ever-evolving pharmaceutical world, where Big Pharma is increasingly seeing common goals in aligning with generic drug companies, GlaxoSmithKline and Dr. Reddy's Labs recently entered into a strategic alliance to reach out to untapped emerging markets for generic drugs. While it is apparent that large pharmaceutical companies see emerging markets as their next big bet, how are generic drug makers responding? To find out, PharmAsia News India bureau caught up with G.V. Prasad, vice chairman of Dr. Reddy's Labs, who shaped the future for his company, from generic drugs to researching new compounds.
You may also be interested in...
Dr. Reddy's Has All Guns Blazing On Biosimilars; Plans To Go After Top 10
The Indian company has captured over half of the rituximab segment in the local market, earning close to $6 million in just over a year's time after launch of Rituxan generic Reditux.
Dr. Reddy's Has All Guns Blazing On Biosimilars; Plans To Go After Top 10
The Indian company has captured over half of the rituximab segment in the local market, earning close to $6 million in just over a year's time after launch of Rituxan generic Reditux.
India's Dr. Reddy's Has All Guns Blazing On Biosimilars; Plans To Go After Top 10
HYDERABAD, India - Enthused by the success of its first monoclonal antibody Reditux - a copy of Genentech's Rituxan (rituximab) - India's Dr. Reddy's Labs is making a full throttle attempt to develop and launch copies of most blockbuster biotech drugs available in the international markets